Physician profile
Jeffrey A Ali
NPI 1164468468
$2,502.29
in general payments reported to CMS, 2019-2025
17 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $250 · 2021: $581 · 2022: $66.68 · 2023: $404 · 2024: $546 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $383.33 | 2021-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $360.05 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $282.64 | 2019-2023 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $241.25 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $230.58 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $225.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $208.84 | 2019-2024 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $147.34 | 2020-2022 | |
| Lundbeck LLC | $108.86 | 2020-2025 | Abilify Asimtufii |
| Bioxcel Therapeutics, INC. | $97.16 | 2023 | Igalmi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.07 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.61 | 2020-2021 | |
| Livanova USA, INC. | $24.46 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.04 | 2025 | Abilify Asimtufii |
| Stryker Corporation | $17.71 | 2023 | Procuity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $15.69 | 2021 | |
| Allergan, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.